Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00015288 · ClinicalTrials.gov registry record · Phase 1

Buprenorphine and Naloxone Combination Study - 10

A Phase 1 study of Opioid-Related Disorders and Heroin Dependence, sponsored by National Institute on Drug Abuse (NIDA).

Completed
Registry status
Phase 1
Development phase
1
Study location

NCT00015288: Completed Phase 1 study of Opioid-Related Disorders and Heroin Dependence, sponsored by National Institute on Drug Abuse (NIDA).

NCT00015288 is a Phase 1 study of Opioid-Related Disorders and Heroin Dependence that has completed, run by National Institute on Drug Abuse (NIDA). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00015288, a Phase 1 study of Opioid-Related Disorders and Heroin Dependence, has completed, sponsored by National Institute on Drug Abuse (NIDA).

COMPLETED
Registry status
Phase 1
Development phase
1
Study location

Study Summary

The purpose of this study is to examine pharmacokinetics and dose proportionality of sublingual tablets containing varying doses of buprenorphine and naloxone.

Interventions

  • DRUG Buprenorphine/naloxone

Study Locations (1)

New York

  • New York MDRU - New York

Trial Details

FieldValue
Start Date 1996-11
Phase Phase 1

What the finished NCT00015288 record still lists

NCT00015288 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.

The record links to 2 conditions, with Opioid-Related Disorders appearing as the primary indexed condition, and to 1 intervention - of which Buprenorphine/naloxone is the first listed.

NCT00015288 reports a single indexed study location in New York.

Frequently Asked Questions

What is clinical trial NCT00015288 about?

NCT00015288 is a clinical study titled "Buprenorphine and Naloxone Combination Study - 10". The purpose of this study is to examine pharmacokinetics and dose proportionality of sublingual tablets containing varying doses of buprenorphine and naloxone.

What is the current status of trial NCT00015288?

This trial is currently completed. It is a Phase 1 study. The study started on 1996-11.

What conditions does trial NCT00015288 study?

This clinical trial studies the following conditions: Opioid-Related Disorders, Heroin Dependence.

What interventions are being tested in trial NCT00015288?

The interventions under investigation include: Buprenorphine/naloxone (DRUG).

Who is sponsoring clinical trial NCT00015288?

This trial is sponsored by National Institute on Drug Abuse (NIDA), which has 335 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00015288 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00015288, the US trial registry maintained by the National Library of Medicine. NCT00015288 (unsized enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.